Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 3.92Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 3.92Mです。
割高
同社の最新のPEは-0.06で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は11.14M株で、前四半期比で2.69%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を63.64K株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は10.46です。